Market Research Logo

Eisai Co., Ltd. - Product Pipeline Review - 2016

Eisai Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Eisai Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Eisai Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eisai Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Eisai Co., Ltd.
  • The report provides overview of Eisai Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Eisai Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Eisai Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Eisai Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Eisai Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Eisai Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Eisai Co., Ltd. Snapshot
Eisai Co., Ltd. Overview
Key Information
Key Facts
Eisai Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Eisai Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Eisai Co., Ltd. - Pipeline Products Glance
Eisai Co., Ltd. - Late Stage Pipeline Products
Eisai Co., Ltd. - Clinical Stage Pipeline Products
Eisai Co., Ltd. - Early Stage Pipeline Products
Eisai Co., Ltd. - Drug Profiles
donepezil hydrochloride
eribulin mesylate
lenvatinib mesylate
lorcaserin hydrochloride
mitiglinide
perampanel
clevudine
mecobalamin
avatrombopag
fosravuconazole
lemborexant
BAN-2401
denileukin diftitox
E-2609
E-3710
E-7820
indisulam
Vaccine for Metastatic Melanoma
E-6011
E-6201
E-7449
golvatinib + lenvatinib
golvatinib tartrate
tazemetostat
donepezil hydrochloride Patch
E-2027
E-7046
E-7090
E-7389LF
SJ-733
AT-791
E-2072
E-2508
E-5539
E-6446
ER-358063
ER-410660
ER-886046
ER-901356
Small Molecule for Epilepsy
Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders
Small Molecule to Inhibit Cytidine Deaminase for Oncology
Small Molecule to Inhibit GWT1 Protein for Malaria
E-209
Small Molecules for Bacterial Infections
Small Molecules for Chagas Disease
Small Molecules for Lymphatic Filariasis and Onchocerciasis
Small Molecules for Malaria
Small Molecules for Oncology
Small Molecules for Tuberculosis
TRI-4
Eisai Co., Ltd. - Pipeline Analysis
Eisai Co., Ltd. - Pipeline Products by Target
Eisai Co., Ltd. - Pipeline Products by Route of Administration
Eisai Co., Ltd. - Pipeline Products by Molecule Type
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action
Eisai Co., Ltd. - Recent Pipeline Updates
Eisai Co., Ltd. - Dormant Projects
Eisai Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Eisai Co., Ltd. - Company Statement
Eisai Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Eisai Co., Ltd., Key Information
Eisai Co., Ltd., Key Facts
Eisai Co., Ltd. - Pipeline by Indication, 2016
Eisai Co., Ltd. - Pipeline by Stage of Development, 2016
Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2016
Eisai Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
Eisai Co., Ltd. - Partnered Products in Pipeline, 2016
Eisai Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2016
Eisai Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Eisai Co., Ltd. - Pre-Registration, 2016
Eisai Co., Ltd. - Filing rejected/Withdrawn, 2016
Eisai Co., Ltd. - Phase III, 2016
Eisai Co., Ltd. - Phase II, 2016
Eisai Co., Ltd. - Phase I, 2016
Eisai Co., Ltd. - Preclinical, 2016
Eisai Co., Ltd. - Discovery, 2016
Eisai Co., Ltd. - Pipeline by Target, 2016
Eisai Co., Ltd. - Pipeline by Route of Administration, 2016
Eisai Co., Ltd. - Pipeline by Molecule Type, 2016
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Eisai Co., Ltd. - Recent Pipeline Updates, 2016
Eisai Co., Ltd. - Dormant Developmental Projects,2016
Eisai Co., Ltd. - Discontinued Pipeline Products, 2016
Eisai Co., Ltd., Subsidiaries
List of Figures
Eisai Co., Ltd. - Pipeline by Top 10 Indication, 2016
Eisai Co., Ltd. - Pipeline by Stage of Development, 2016
Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2016
Eisai Co., Ltd. - Partnered Products in Pipeline, 2016
Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2016
Eisai Co., Ltd. - Pipeline by Top 10 Target, 2016
Eisai Co., Ltd. - Pipeline by Route of Administration, 2016
Eisai Co., Ltd. - Pipeline by Molecule Type, 2016
Eisai Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report